Evaluation of the Active Warming Effects on Maternal and Neonatal Outcome During Cesarean Delivery

NCT ID: NCT03473470

Last Updated: 2020-09-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-22

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective randomized study of healthy term parturients undergoing cesarean delivery was designed to assess the impact of the active warming on perioperative and postoperative temperature.

The main objective is to evaluate the maternal core temperature in the perioperative and postoperative period during cesarean delivery.

The secondary objectives are to assess the incidence of maternal hypothermia, the incidence of maternal shivers, the evaluation of maternal thermal comfort, the neonatal temperature at birth, the Apgar score at 1 and 5 minutes, the umbilical pH, the evaluation of coagulative assessment in case of maternal hypothermia trough the use of thromboelastography.

The patients are randomized into three groups: a group of no warmed patients, a second group of Active waming patients with iv fluids and lower body forced air warming and a third group of Active warming patients with only warmed iv fluids.

The inclusion criteria are healthy parturients up to age 18. The exclusion criteria included parturients who develop fever, diabetes mellitus, BMI up to 40kg/ m2, coagulative disorders, pre eclampsia or eclampsia, all the factors that can cause intraoperative bleeding such as placental abruption or antecedent placenta overgrowth ( placenta previa).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The doctor's main purposes during the perioperative period are the monitorign and maintenance of normothermia, as well as the haemodynamic, respiratory, metabolic, analgesic control and monitoring.

Mild hypothermia ( core temperature between 36° and 33° C) is common during general, locoregional or blended anaesthesia. A mild hypothermia can cause a cardiovascular, haematological, metaolic and hormonal alterations that can explain an increased mortality and morbidity in hypothermia patients versus normothermia patients.

Thermic decrease is a physiological event during general or locoregional anaesthesia. Particularly spinal and epidural anaesthesia can cause the thermic decrease because of vasodilation below the level of the sensitive and neuroaxial blockade. In this way there is in the patient an increased heat loss trough radiation. The neuroaxial techniques can reduce the sensory connections and the level of vasoconstriction above the level of the sensorial blockade, reducing the patient capacity to maintain the poichilothermia.

The consequences of hypothermia are important because they can influence the intraoperative management causing complications extending the recovering time and the hospitalization.

The environmental temperature is a critical factor for the development of hypothermia , especially in critically patients. In order to avoid the deveopment of hypothermia the environmental temperature must be maintainde between 21° and 24° C and humidity level of 40- 60%.

Maternal hypothermia is common during cesarean delivery and it can exercise influence over neonatal temperature.

When a mother develops hypothermia the newborn can shows hypotheria, umbilical acidosis, low Apgar score at birth.

The recorded data are the demographic data of the patient such as weight, age and height, the vital signs such as heart rate, arterial pressure, SpO2 or EtCO2 during general anaesthesia, BMI, gestational age and parity, type of anaesthesia, doses and type of anaesthetic used, the development of adverse effects such as hypothermia or hypothension, the blood leaks, the environmental temperature on operative theatre, the temperature of fluids iv in the perioperative period, the maternal core temperature at preoperative, during induction of anaesthesia, after 5 minutes initiating anaesthesia, and then every 10 minutes until the end of the cesarean delivery and also at child birth, at the exit of operative theatre. Maternal temperature measurment will be obtained by using a skin sensor Spot On on a temporal region, the neonatal axillary temperature at 1 and5 minutes from birth using a digital thermometer, Apgar score and umbilical cord blood pH, the pain evaluation using a VAS scale ( 0-10), the maternal shivering by the Bedside Shivering Assessment scale, the maternal comfort using a verbal numerical scale ( 0 = as worst immaginable cold 50= as thermoneutral and 100= as insufferably hot), the timing of pain at induction of anaesthesia and then every 10 minutes until the operative room exit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothermia; Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

not warmed

Not warming system

Group Type NO_INTERVENTION

No interventions assigned to this group

warmed group 1

forced air warming and warmed intravenous fluids

Group Type ACTIVE_COMPARATOR

forced air warming and warmed intravenous fluids

Intervention Type DEVICE

Use of warming system (forced air)

warmed group 2

warmed intravenous fluids

Group Type ACTIVE_COMPARATOR

warmed intravenous fluids

Intervention Type DEVICE

Use of warming system to have warmed intravenous fluids

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

forced air warming and warmed intravenous fluids

Use of warming system (forced air)

Intervention Type DEVICE

warmed intravenous fluids

Use of warming system to have warmed intravenous fluids

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Fever;
* Diabetes mellitus;
* BMI\> 40Kg/m²;
* Coaugulation disorders;
* Pre-eclampsia and eclampsia;
* Increased risk of intraoperative hemorrhage
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Foggia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cotoia Antonella

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonella Cotoia, MD

Role: PRINCIPAL_INVESTIGATOR

University of Foggia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedali Riuniti

Foggia, Apulia, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Antonella Cotoia, MD

Role: CONTACT

+393297174175

Gilda Cinnella, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Antonella Cotoia, MD

Role: primary

+39 3297174175

Gilda Cinnella, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

76/CE/2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.